Clinical Innovation

"The effectiveness of these therapies has brought about a wave of innovation and clinical exploration. The success of Pluvicto in targeting prostate-specific membrane antigen (PSMA)–expressing prostate tumors has led to a four-fold increase in radiopharmaceutical use in metastatic prostate cancer since 2021, and radiopharmaceuticals now represent the second most common treatment for these patients after chemotherapy (497)Global Oncology Trends 2025. Accessed: June 11, 2025.. The field is also advancing rapidly in breast cancer, for which clinical trials are exploring investigational RLTs in combination with bispecific antibodies and immunotherapies to overcome tumor heterogeneity and enhance immune activation (562)Giugliano F, et al. (2025) Cancer Treat Rev, 136: 102940.."